Use of distinct anti‐hypertensive drugs and risk for COVID‐19 among hypertensive people: A population‐based cohort study in Southern Catalonia, Spain

{ 'indexed': {'date-parts': [[2024, 5, 13]], 'date-time': '2024-05-13T13:25:53Z', 'timestamp': 1715606753396}, 'reference-count': 28, 'publisher': 'Wiley', 'issue': '8', 'license': [ { 'start': { 'date-parts': [[2020, 7, 25]], 'date-time': '2020-07-25T00:00:00Z', 'timestamp': 1595635200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor'}], 'funder': [ { 'DOI': '10.13039/501100004587', 'name': 'Instituto de Salud Carlos III', 'doi-asserted-by': 'publisher', 'award': ['COV20/00852']}], 'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2020, 8]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>The use of some anti‐hypertensive drugs in the ' 'current COVID‐19 pandemic has become controversial. This study investigated possible ' 'relationships between anti‐hypertensive medications use and COVID‐19 infection risk in the ' 'ambulatory hypertensive population. This is a population‐based retrospective cohort study ' 'involving 34\xa0936 hypertensive adults &gt;50\xa0years in Tarragona (Southern Catalonia, ' 'Spain) who were retrospectively followed through pandemic period (from 01/03/2020 to ' '30/04/2020). Two data sets including demographic/clinical characteristics (comorbidities and ' 'cardiovascular medications use) and laboratory PCR codes for COVID‐19 were linked to ' 'construct an anonymized research database. Cox regression was used to calculate multivariable ' 'hazard ratios (HRs) and estimate the risk of suffering COVID‐19 infection. Across study ' 'period, 205 PCR‐confirmed COVID‐19 cases were observed, which means an overall incidence of ' '586.8 cases per 100\xa0000 persons‐period. In multivariable analyses, only age (HR: 1.03; 95% ' 'CI: 1.02‐1.05; <jats:italic>P</jats:italic>\xa0&lt;\xa0.001) and nursing home residence (HR: ' '19.60; 95% CI: 13.80‐27.84; <jats:italic>P</jats:italic>\xa0&lt;\xa0.001) appeared ' 'significantly associated with increased risk of COVID‐19. Considering anti‐hypertensive ' 'drugs, receiving diuretics (HR: 1.22; 95% CI: 0.90‐1.67; <jats:italic>P</jats:italic>\xa0=\xa0' '.205), calcium channel blockers (HR: 1.29; 95%CI: 0.91‐1.82; <jats:italic>P</jats:italic>\xa0' '=\xa0.148), beta‐blockers (HR: 0.97; 95% CI: 0.68‐1.37; <jats:italic>P</jats:italic>\xa0=\xa0' '.844), and angiotensin‐converting enzyme inhibitors (HR: 0.83; 95% CI: 0.61‐1.13; ' '<jats:italic>P</jats:italic>\xa0=\xa0.238) did not significantly alter the risk of ' 'PCR‐confirmed COVID‐19, whereas receiving angiotensin II receptor blockers was associated ' 'with an almost statistically significant reduction risk (HR: 0.67; 95% CI: 0.44‐1.01; ' '<jats:italic>P</jats:italic>\xa0=\xa0.054). In conclusion, our data support that receiving ' 'renin‐angiotensin‐aldosterone system inhibitors does not predispose for suffering COVID‐19 ' 'infection in ambulatory hypertensive people. Conversely, receiving angiotensin II receptor ' 'blockers could be related with a reduced risk.</jats:p>', 'DOI': '10.1111/jch.13948', 'type': 'journal-article', 'created': {'date-parts': [[2020, 7, 25]], 'date-time': '2020-07-25T15:53:36Z', 'timestamp': 1595692416000}, 'page': '1379-1388', 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 31, 'title': 'Use of distinct anti‐hypertensive drugs and risk for COVID‐19 among hypertensive people: A ' 'population‐based cohort study in Southern Catalonia, Spain', 'prefix': '10.1111', 'volume': '22', 'author': [ { 'given': 'Angel', 'family': 'Vila‐Corcoles', 'sequence': 'first', 'affiliation': [ { 'name': 'Primary Health Care Service Camp de Tarragona Institut Catala de ' 'la Salut Tarragona Spain'}, { 'name': 'Unitat de Suport a la Recerca Tarragona‐Reus IDIAP Jordi Gol ' 'Barcelona Spain'}]}, { 'given': 'Eva', 'family': 'Satue‐Gracia', 'sequence': 'additional', 'affiliation': [ { 'name': 'Primary Health Care Service Camp de Tarragona Institut Catala de ' 'la Salut Tarragona Spain'}, { 'name': 'Unitat de Suport a la Recerca Tarragona‐Reus IDIAP Jordi Gol ' 'Barcelona Spain'}]}, { 'ORCID': 'http://orcid.org/0000-0002-7015-0018', 'authenticated-orcid': False, 'given': 'Olga', 'family': 'Ochoa‐Gondar', 'sequence': 'additional', 'affiliation': [ { 'name': 'Primary Health Care Service Camp de Tarragona Institut Catala de ' 'la Salut Tarragona Spain'}, { 'name': 'Unitat de Suport a la Recerca Tarragona‐Reus IDIAP Jordi Gol ' 'Barcelona Spain'}]}, { 'given': 'Cristina', 'family': 'Torrente‐Fraga', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Information and Communication Technologies DAP ' 'Camp de Tarragona Institut Catala de la Salut Tarragona Spain'}]}, { 'given': 'Frederic', 'family': 'Gomez‐Bertomeu', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Microbiology Hospital Universitari Joan XXIII ' 'Institut Catala de la Salut Tarragona Spain'}]}, { 'given': 'Angel', 'family': 'Vila‐Rovira', 'sequence': 'additional', 'affiliation': [ { 'name': 'Unitat de Suport a la Recerca Tarragona‐Reus IDIAP Jordi Gol ' 'Barcelona Spain'}]}, { 'given': 'Imma', 'family': 'Hospital‐Guardiola', 'sequence': 'additional', 'affiliation': [ { 'name': 'Primary Health Care Service Camp de Tarragona Institut Catala de ' 'la Salut Tarragona Spain'}]}, { 'given': 'Cinta', 'family': 'de Diego‐Cabanes', 'sequence': 'additional', 'affiliation': [ { 'name': 'Primary Health Care Service Camp de Tarragona Institut Catala de ' 'la Salut Tarragona Spain'}]}, { 'given': 'Ferran', 'family': 'Bejarano‐Romero', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Farmacology DAP Camp de Tarragona Institut Catala ' 'de la Salut Tarragona Spain'}]}, { 'given': 'Dolors', 'family': 'Rovira‐Veciana', 'sequence': 'additional', 'affiliation': [{'name': 'Department of Laboral Medicine ACTIVA Mutua Tarragona Spain'}]}, { 'given': 'Josep', 'family': 'Basora‐Gallisa', 'sequence': 'additional', 'affiliation': [ { 'name': "Fundació Institut Universitari per a la recerca a l'Atenció " 'Primària de Salut Jordi Gol i Gurina (IDIAPJGol) Barcelona ' 'Spain'}]}], 'member': '311', 'published-online': {'date-parts': [[2020, 7, 25]]}, 'reference': [ { 'key': 'e_1_2_10_2_1', 'unstructured': 'World Health Organization.Coronavirus disease 2019 (COVID‐19): situation ' 'report‐87 ' 'https://www.who.int/docs/default‐source/coronaviruse/situation‐reports/20200416‐sitrep‐87‐covid‐19.pdf?sfvrsn=9523115a_2(2020 ' '[accessed 10 May 2020].'}, {'key': 'e_1_2_10_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijid.2020.03.017'}, {'key': 'e_1_2_10_4_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.5394'}, { 'key': 'e_1_2_10_5_1', 'first-page': '49', 'article-title': 'Continuing versus suspending angiotensin‐converting enzyme inhibitors ' 'and angiotensin receptor blockers: impact on adverse outcomes in ' 'hospitalized patients with severe acute respiratory syndrome ' 'coronavirus 2 (SARS‐CoV‐2) [published online ahead of print, 2020 May ' '13]', 'author': 'Lopes RD', 'year': '2020', 'journal-title': 'Am Heart J'}, { 'key': 'e_1_2_10_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/HJH.0000000000002450'}, { 'key': 'e_1_2_10_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/HJH.0000000000002472'}, {'key': 'e_1_2_10_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JVI.00127-20'}, {'key': 'e_1_2_10_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2006923'}, { 'key': 'e_1_2_10_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)31030-8'}, {'key': 'e_1_2_10_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2008975'}, { 'key': 'e_1_2_10_12_1', 'unstructured': 'World Medical Association.WMA Declaration of Helsinki – Ethical ' 'Principles for Medical Research Involving Human Subjects. Available ' 'at:https://www.wma.net/policies‐post/wma‐declaration‐of‐helsinki‐ethical‐principles‐for‐medical‐research‐involving‐human‐subjects/. ' '[Accessed May 14 2020].'}, {'key': 'e_1_2_10_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/1471-2458-10-25'}, { 'key': 'e_1_2_10_14_1', 'unstructured': 'Generalitat de Catalunya.Sub‐direcció General de Vigilància i Resposta a ' 'Emergències de Salut Pública. Procediment d’actuació enfront de casos ' 'd’infecció pel nou coronavirus SARS‐CoV‐2. Available ' 'at:https://canalsalut.gencat.cat/web/.content/_A‐Z/C/coronavirus‐2019‐ncov/material‐divulgatiu/procediment‐actuacio‐coronavirus.pdf[Accessed ' 'May 16 2020].'}, {'key': 'e_1_2_10_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JCM.00821-20'}, { 'key': 'e_1_2_10_16_1', 'unstructured': 'Who Collaborating Centre for Drug Statistics Methodology.ATC/DDD Index ' '2020 Available at:https://www.whocc.no/atc_ddd_index/[Accessed May 12 ' '2020].'}, { 'key': 'e_1_2_10_17_1', 'volume-title': 'Applied Survival Analysis. Regression Modeling of Time to Event Data', 'author': 'Hosmer DW', 'year': '1999'}, { 'key': 'e_1_2_10_18_1', 'unstructured': 'Consumo. Dirección General de Salud Pública Calidad e innovación. Centro ' 'de Coordinación de Alertas y Emergencias Sanitarias.Información ' 'científica‐técnica. Enfermedad por coronavirus COVID19. Actualización 17 ' 'de abril Available ' 'at:https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov‐China/documentos/20200417_ITCoronavirus.pdf[Accessed ' 'May 5 2020].'}, { 'key': 'e_1_2_10_19_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s13054-020-02902-w'}, { 'key': 'e_1_2_10_20_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijid.2020.03.017'}, { 'key': 'e_1_2_10_21_1', 'first-page': 'cvaa097', 'article-title': 'Hypertension, the renin–angiotensin system, and the risk of lower ' 'respiratory tract infections and lung injury: implications for COVID‐19', 'author': 'Kreutz R', 'year': '2020', 'journal-title': 'Cardiovasc Res'}, { 'key': 'e_1_2_10_22_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1161/CIRCRESAHA.120.317134'}, {'key': 'e_1_2_10_23_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41440-020-0455-8'}, {'key': 'e_1_2_10_24_1', 'doi-asserted-by': 'publisher', 'DOI': '10.5114/aoms.2020.94655'}, {'key': 'e_1_2_10_25_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/jth.14871'}, {'key': 'e_1_2_10_26_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMe2012924'}, { 'key': 'e_1_2_10_27_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s40885-020-00144-0'}, { 'key': 'e_1_2_10_28_1', 'unstructured': 'European Society of Cardiology.Position Statement of the ESC Council on ' 'Hypertension on ACE‐Inhibitors and Angiotensin Receptor Blockers ' 'Available ' 'at:https://www.escardio.org/Councils/Council‐on‐Hypertension‐(CHT)/News/position‐statement‐of‐the‐esc‐council‐on‐hypertension‐on‐ace‐inhibitors‐and‐ang[Accessed ' 'May 15 2020].'}, { 'key': 'e_1_2_10_29_1', 'unstructured': 'American Heart Association.HFSA/ACC/AHA statement addresses concerns re: ' 'using RAAS antagonists in COVID‐19 Available ' 'at:https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHA‐statement‐addresses‐concerns‐re‐using‐RAAS‐antagonists‐in‐COVID‐19.jsp[Accessed ' 'May 15 2020].'}], 'container-title': 'The Journal of Clinical Hypertension', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fjch.13948', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1111/jch.13948', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/full-xml/10.1111/jch.13948', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1111/jch.13948', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 9, 5]], 'date-time': '2023-09-05T19:59:50Z', 'timestamp': 1693943990000}, 'score': 1, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1111/jch.13948'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 7, 25]]}, 'references-count': 28, 'journal-issue': {'issue': '8', 'published-print': {'date-parts': [[2020, 8]]}}, 'alternative-id': ['10.1111/jch.13948'], 'URL': 'http://dx.doi.org/10.1111/jch.13948', 'relation': {}, 'ISSN': ['1524-6175', '1751-7176'], 'subject': [], 'container-title-short': 'J of Clinical Hypertension', 'published': {'date-parts': [[2020, 7, 25]]}, 'assertion': [ { 'value': '2020-06-02', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2020-07-06', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2020-07-25', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}